513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
RadNet reported third quarter 2024 revenue of $461.1 million, up 14.7%, and Adjusted EBITDA of $73.7 million, up 27.2%, with Adjusted diluted EPS of $0.18 versus $0.13. GAAP net income attributable to common stockholders fell to $3.2 million ($0.04 per diluted share) from $17.5 million ($0.25), and the company raised its Imaging Center revenue and Adjusted EBITDA guidance for 2024.
Q3 2024 Total Company Revenue was $461.1 million, up from $402.0 million; Adjusted EBITDA was $73.7 million, up from $57.9 million.
GAAP net income attributable to RadNet common stockholders was $3.2 million, or $0.04 per diluted share, versus $17.5 million, or $0.25, in Q3 2023; the company cited an $8.1 million non-cash loss from interest rate swaps among one-time ite
Adjusted diluted EPS was $0.18 versus $0.13 a year earlier.
Imaging Center 2024 guidance now projects Total Net Revenue of $1,710 - $1,760 million (up from $1,685 - $1,735 million) and Adjusted EBITDA of $262 - $270 million (up from $257 - $267 million).
CAVA Group reported fiscal third-quarter 2024 results for the period ended October 6, 2024, with CAVA segment revenue up 39.0% and net income rising to $18.0 million from $6.8 million a year earlier. The company also raised its fiscal 2024 guidance, lifting its Adjusted EBITDA forecast to $121.0 million to $126.0 million from $109.0 million to $114.0 million.
CAVA Revenue grew 39.0% to $241.5 million, versus $173.8 million in the prior-year quarter.
Net income was $18.0 million, or $0.15 per diluted share, compared with $6.8 million, or $0.06 per diluted share, a year earlier.
Fiscal 2024 guidance raised: CAVA Same Restaurant Sales Growth to 12.0% to 13.0% from 8.5% to 9.5%, and Adjusted EBITDA to $121.0 million to $126.0 million from $109.0 million to $114.0 million.
CAVA Restaurant-Level Profit Margin was 25.6%, compared with 25.1% in the prior-year quarter.
ePlus reported fiscal second-quarter results for the three months ended September 30, 2024, with net sales down 12.3% and diluted earnings per share down to $1.17 from $1.22. Consolidated gross profit rose 2.5%, helped by services and financing revenue, and the company now expects fiscal 2025 net sales similar to fiscal 2024 and adjusted EBITDA of $195 million to $205 million.
Q2 net sales fell 12.3% to $515.2 million; product sales fell 22.2% to $389.6 million, while services revenue rose 46.0% to $103.7 million
Consolidated gross profit rose 2.5% to $148.0 million, and gross margin was 28.7%, compared with 24.6% a year earlier
Net earnings fell 4.1% to $31.3 million; adjusted EBITDA fell 2.7% to $52.1 million
Fiscal 2025 guidance: net sales now expected to be similar to fiscal 2024; adjusted EBITDA now expected at $195 million to $205 million
Rocket Lab reported third-quarter 2024 results on November 12, 2024. Revenue rose 55% year over year to $104.8 million, but the net loss widened to $51.9 million from $40.6 million, and the adjusted EBITDA loss grew to $30.9 million from $15.5 million. The company guided fourth-quarter revenue to $125 million to $135 million, which it describes as a record quarter.
Q3 2024 revenue was $104.8 million, up from $67.7 million in Q3 2023.
Net loss was $51.9 million, or $0.10 per share, compared with $40.6 million, or $0.08 per share, a year earlier.
Q4 2024 guidance calls for revenue of $125 million to $135 million and GAAP gross margins of 26% to 28%.
CEO Sir Peter Beck cited a backlog of $1.05 billion.
BioLife Solutions reported unaudited third-quarter 2024 revenue of $30.6 million, up 30% from a year earlier, and a GAAP net loss from continuing operations of $1.7 million, down from $15.8 million. The company also completed the $73.0 million cash sale of its SciSafe biostorage subsidiary on November 12, 2024, and cut its full-year 2024 total revenue guidance to $98.0 million to $100.0 million from $99.0 million to $101.0 million, citing the divestiture.
Q3 2024 total revenue was $30.6 million, up from $23.6 million in Q3 2023 and up 8% sequentially.
Q3 2024 GAAP net loss from continuing operations was $1.7 million, or $0.04 per share, versus $15.8 million, or $0.36 per share, a year earlier.
Adjusted EBITDA was $6.1 million, or 20% of revenue, compared with $1.4 million, or 6%, in Q3 2023.
Cell Processing 2024 revenue guidance was raised to $72.0 million to $73.0 million, while Biostorage Services guidance was lowered to $26.0 million to $27.0 million.
Dave Inc. reported third-quarter 2024 revenue of $92.5 million, up 41% from a year earlier, and net income of $0.5 million, compared with a net loss of $12.1 million in the same quarter of 2023. The company raised its full-year 2024 revenue guidance to $340 million to $343 million and its Adjusted EBITDA guidance to $71 million to $74 million, which is a positive signal for shareholders on both growth and profitability.
Q3 2024 revenue was $92.5 million, up 41% year over year, and net income was $0.5 million versus a $12.1 million loss in Q3 2023.
Q3 2024 Adjusted EBITDA was $24.7 million, compared with a $2.5 million loss in Q3 2023.
Full-year 2024 revenue guidance was raised to $340 million to $343 million from $310 million to $325 million.
Full-year 2024 Adjusted EBITDA guidance was raised to $71 million to $74 million from $40 million to $50 million.
ICU Medical reported third quarter 2024 revenue of $589.1 million, up from $553.3 million a year earlier, but swung to a GAAP net loss of $33.0 million from net income of $7.2 million. The company also widened its full-year 2024 GAAP net loss outlook, while narrowing its adjusted EBITDA range, so shareholders face a mixed picture on reported results and updated guidance.
Q3 2024 revenue was $589.1 million, up from $553.3 million in Q3 2023.
GAAP net loss was $33.0 million, or $1.35 per diluted share, versus net income of $7.2 million, or $0.30 per share, a year earlier.
Adjusted diluted EPS was $1.59 versus $1.57, and adjusted EBITDA was $94.8 million versus $89.8 million.
FY2024 GAAP net loss outlook moved to $122 million to $130 million from $108 million to $118 million; adjusted EBITDA outlook is now $355 million to $365 million.
NCR Atleos reported third quarter 2024 results on November 12, 2024. Revenue was $1.08 billion, up from $1.07 billion a year earlier, and GAAP net income attributable to Atleos was $24 million, compared with a net loss of $58 million a year earlier. The company reaffirmed its full-year 2024 guidance and said non-GAAP EPS guidance moved to the high end of its range, which matters to shareholders because it signals results ahead of the company's prior expectations.
Q3 revenue $1.08 billion vs. $1.07 billion a year earlier; Adjusted EBITDA $207 million vs. $210 million
GAAP diluted EPS $0.32 vs. loss of $0.82 a year earlier; non-GAAP diluted EPS $0.89
Full-year 2024 non-GAAP diluted EPS guidance of approximately $3.12, versus previous range of $2.90 to $3.20
October 17, 2024 debt refinancing reduced spread to SOFR by about 100 basis points on roughly $1.7 billion of variable rate debt
ZoomInfo reported third quarter 2024 results with GAAP revenue of $303.6 million, down 3% from a year earlier, and GAAP operating income of $43.5 million, down 31%. It raised its full-year 2024 adjusted net income per share guidance to $0.92-$0.93, from $0.86-$0.88 previously, while narrowing its full-year revenue guidance to $1.201-$1.204 billion.
Q3 2024 GAAP revenue was $303.6 million, down 3% year over year; GAAP diluted EPS was $0.07 versus $0.08 a year earlier.
Adjusted net income per share rose to $0.28 from $0.26, and adjusted operating income was $111.7 million, down 11%.
Full-year 2024 adjusted EPS guidance was raised to $0.92-$0.93; GAAP revenue guidance is $1.201-$1.204 billion, versus $1.190-$1.205 billion previously.
The company repurchased 24,478,696 shares for $242.1 million in the quarter, and has repurchased about 17% of outstanding shares since a buyback began in March 2023.
Maplebear Inc. (Instacart) reported third-quarter 2024 results on November 12, 2024, with GTV of $8,303 million, up 11% year-over-year, and total revenue of $852 million, up 12%. GAAP net income was $118 million and adjusted EBITDA was $227 million, up 39%, and the company gave a fourth-quarter GTV outlook of $8,500 million to $8,650 million. On November 5, 2024, the Board raised the share repurchase authorization to $750 million from $500 million, which matters to shareholders because it adds capacity to buy back stock.
Total revenue was $852 million, up 12% year-over-year; GAAP net income was $118 million, the fourth straight quarter of positive GAAP net income.
Adjusted EBITDA was $227 million, up 39%; operating cash flow was $185 million, up 67%.
Q4 2024 outlook: GTV of $8,500 million to $8,650 million and adjusted EBITDA of $230 million to $240 million.
Board approved a buyback of up to $750 million on November 5, 2024, up from $500 million authorized in June 2024; about $68 million remained under the previous program as of September 30, 2024.
Perdoceo reported third-quarter 2024 revenue of $169.8 million, down 5.6% from the prior year quarter, and diluted EPS of $0.57 versus $0.62. The company raised its full-year 2024 outlook, with adjusted EPS now expected at $2.25 to $2.28, while revenue and reported EPS declined in the quarter.
Q3 2024 revenue $169.8 million, down 5.6%; year-to-date revenue $504.8 million, down 10.2%
Q3 diluted EPS $0.57 vs. $0.62; adjusted diluted EPS $0.59 vs. $0.64
Q3 operating income up 4.0% to $44.8 million; enrollments up 11.0% to 40,400
Full-year 2024 adjusted EPS outlook $2.25 to $2.28 vs. $2.10 in 2023; quarterly dividend of $0.13 per share payable December 13, 2024
Sunstone Hotel Investors reported third-quarter 2024 net income of $3.2 million, down from $15.6 million a year earlier, and lowered its full-year 2024 net income and Adjusted FFO per share guidance, citing labor activity at the Hilton San Diego Bayfront, Florida weather and a slower recovery in Maui. The company also entered a $100 million unsecured delayed draw term loan that it expects to draw in early December to repay a $72.1 million loan secured by the JW Marriott New Orleans, which it says would leave all its hotels unencumbered and no debt maturities before 2026.
Q3 2024 net income was $3.2 million versus $15.6 million in Q3 2023; Adjusted EBITDAre fell 15.9% to $53.6 million
Adjusted FFO per diluted share was $0.18 versus $0.23, down 21.7%; comparable RevPAR fell 1.3% to $207.56
Full-year 2024 net income guidance is now $31 million to $41 million, down from $43 million to $53 million; Adjusted FFO per share guidance is $0.75 to $0.80, down from $0.79 to $0.84
The $100 million term loan matures November 7, 2025, with two six-month extension options; the company repurchased 2,688,582 shares year to date through November 11, 2024
Repligen reported third-quarter 2024 revenue of $155 million, up 10% from a year earlier, and narrowed its full-year 2024 revenue guidance to $630 million-$639 million while keeping the midpoint unchanged. GAAP results swung to a small loss, which the company attributed in part to $17.4 million of incremental stock compensation tied to the CEO's transition to Executive Chair, and the filing references a prior restatement of financial statements.
Q3 2024 revenue $155 million vs. $141 million in Q3 2023, up 10%
GAAP net loss of $0.7 million, or $0.01 per diluted share, vs. net income of $17 million, or $0.30 per share
Adjusted (non-GAAP) diluted EPS $0.43 vs. $0.23; includes $17.4 million of CEO transition stock compensation excluded from adjusted results
Schrödinger reported third-quarter 2024 total revenue of $35.3 million, down from $42.6 million a year earlier, while software revenue rose 10%. The net loss narrowed to $38.1 million from $62.0 million, mainly due to changes in the fair value of equity investments, and the company raised the low end of its 2024 software revenue growth guidance. The company also said Novartis will pay $150 million upfront under a new collaboration.
Total revenue fell 17% to $35.3 million; software revenue rose 10% to $31.9 million, while drug discovery revenue fell to $3.4 million from $13.7 million.
Software gross margin decreased to 73% from 76%; operating expenses rose to $86.2 million from $79.8 million.
2024 software revenue growth guidance is now 8% to 13%; drug discovery revenue guidance is $20 million to $30 million.
Novartis will pay Schrödinger $150 million upfront under a multi-target collaboration announced November 12, 2024.
Roivant reported results for the quarter ended September 30, 2024, with a net loss attributable to the company of $230.2 million, or $0.31 per share, compared with $304.3 million, or $0.40 per share, a year earlier. Net revenue rose to $4.5 million from $3.6 million, but general and administrative expenses rose to $202.9 million, including $79.1 million of one-time cash retention awards, and the non-GAAP loss from continuing operations widened to $218.7 million from $154.8 million.
Net loss attributable to Roivant was $230.2 million ($0.31 per share) vs. $304.3 million ($0.40 per share) a year earlier.
Revenue, net was $4.5 million vs. $3.6 million; R&D expenses were $143.1 million vs. $114.8 million.
G&A expenses were $202.9 million vs. $88.6 million, including $79.1 million of one-time cash retention awards approved in July 2024.
Cash, cash equivalents and marketable securities were approximately $5.4 billion at September 30, 2024, after $106 million of share repurchases in the quarter.
Sylvamo reported third-quarter 2024 results that improved from the second quarter, with net sales of $965 million, net income of $95 million and diluted EPS of $2.27. The company also expects fourth-quarter 2024 adjusted EBITDA of $150 million to $165 million, below the $193 million reported for the third quarter, and says it will return at least 40% of free cash flow to shareowners this year.
Net sales $965 million vs. $933 million in Q2; net income $95 million ($2.27 per diluted share) vs. $83 million ($1.98).
Adjusted EBITDA $193 million (20% margin) vs. $164 million (18% margin) in Q2; free cash flow $119 million vs. $62 million.
Q4 2024 adjusted EBITDA outlook of $150 million to $165 million, including an $8 million operating expense for a planned turbine generator maintenance event at the Eastover, South Carolina, mill.
Q3 included a $7 million after-tax net special items charge ($0.17 per diluted share).
Mosaic reported third-quarter 2024 net income of $122 million, or $0.38 per diluted share, compared with a net loss of $4 million a year earlier, but revenue fell 21% to $2.8 billion on lower selling prices and adjusted EBITDA dropped to $448 million from $594 million. The company also said CFO Clint Freeland will retire, with Luciano Siani Pires succeeding him as chief financial officer on January 1, 2025.
Q3 2024 net income $122 million ($0.38 per diluted share) vs. net loss of $4 million in Q3 2023; adjusted EPS $0.34 vs. $0.68 a year earlier
Revenue $2.8 billion, down 21% from the year-ago period; adjusted EBITDA $448 million vs. $594 million
Clint Freeland to retire; Luciano Siani Pires joins as CFO designate November 18, 2024 and becomes CFO January 1, 2025
Year-to-date capital return of $415 million, including $210 million of share repurchases
Aramark reported fiscal 2024 revenue of $17.4 billion, up 8%, and operating income of $707 million, up 13%. GAAP earnings per share fell 42% to $0.99 because the prior year included a gain from the sale of its stake in AIM Services, while adjusted EPS rose 35% to $1.55. The board approved a $500 million share repurchase program and an 11% increase in the quarterly dividend, and guided fiscal 2025 adjusted operating income growth of 15% to 18%.
Fiscal 2024 revenue was $17.4 billion, up 8%, with organic revenue up 10%
Operating income rose 13% to $707 million; adjusted operating income rose 20% to $882 million
GAAP EPS was $0.99 versus $1.71 a year earlier; adjusted EPS was $1.55, up 35%
Fiscal 2025 outlook: organic revenue growth of 7.5% to 9.5%, adjusted operating income growth of 15% to 18%, and adjusted EPS growth of 23% to 28%
First Advantage reported third-quarter 2024 revenue of $199.1 million, down 0.6% from a year earlier, and a net loss of $8.9 million versus net income of $10.8 million in the prior-year quarter. The company closed its Sterling acquisition on October 31, 2024, and kept its standalone full-year 2024 guidance while issuing combined-company guidance that includes Sterling, which shareholders will need to weigh against the lower quarterly results.
Q3 2024 revenue was $199.1 million, versus $200.4 million in Q3 2023; adjusted EBITDA was $64.0 million, versus $64.8 million.
GAAP diluted net loss per share was $(0.06), versus diluted net income of $0.07 per share a year earlier; adjusted diluted EPS was $0.26, versus $0.28.
The net loss includes $13.2 million of expenses related to the Sterling acquisition.
Standalone 2024 revenue guidance of $750 million to $800 million was maintained; combined-company revenue guidance is $858 million to $918 million.
Assured Guaranty reported third quarter 2024 GAAP net income of $171 million, or $3.17 per diluted share, up from $157 million, or $2.60, a year earlier. Adjusted operating income, the measure management uses for its core results, fell to $130 million, or $2.42 per share, from $206 million, or $3.42, partly because the 2023 period included a $241 million pre-tax gain from the Sound Point and AHP transactions.
GAAP net income was $171 million, or $3.17 per diluted share, for Q3 2024, versus $157 million, or $2.60, for Q3 2023; the company cited a $54 million foreign exchange gain among pre-tax adjustments.
Adjusted operating income was $130 million, or $2.42 per share, versus $206 million, or $3.42, in Q3 2023.
Q3 2024 capital returned to shareholders totaled $147 million, including $131 million of share repurchases and $16 million of dividends.
On November 8, 2024, the board authorized an additional $250 million of share repurchases; about $385 million remained authorized as of that date.
NW Natural Holdings reported a third-quarter 2024 net loss of $27.2 million ($0.71 per share), wider than the $23.7 million loss a year earlier, on operating revenues of $136.9 million, down 3%. Nine-month net income fell 31% to $33.9 million ($0.88 per share), which the company attributed mainly to regulatory lag, and it reaffirmed its 2024 GAAP EPS guidance of $1.94 to $2.14 while raising its dividend.
Q3 2024 net loss of $27.2 million ($0.71 per share) vs. a net loss of $23.7 million ($0.65 per share) in Q3 2023
Nine-month 2024 net income of $33.9 million ($0.88 per share) vs. $49.2 million ($1.37 per share) in 2023
2024 GAAP EPS guidance of $1.94 to $2.14 reaffirmed; non-GAAP Adjusted guidance of $2.20 to $2.40
Quarterly dividend of 49 cents per share, annual indicated rate $1.96, payable Nov. 15, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.